Show simple item record

dc.contributor.advisorCharles H. Fine.en_US
dc.contributor.authorSingh, Mahender Pal, 1965-en_US
dc.contributor.otherMassachusetts Institute of Technology. Engineering Systems Division.en_US
dc.date.accessioned2006-07-13T15:17:39Z
dc.date.available2006-07-13T15:17:39Z
dc.date.copyright2005en_US
dc.date.issued2005en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/33354
dc.descriptionThesis (M. Eng. in Logistics)--Massachusetts Institute of Technology, Engineering Systems Division, 2005.en_US
dc.descriptionIncludes bibliographical references (leaves 148-150).en_US
dc.description.abstractThis study explores the current supply chain trends in the pharmaceutical industry. The main objective of the study is to characterize the pharmaceutical industry and identify excellent supply chain practices. Indeed, the pharmaceutical industry is not renowned for its supply chain management capabilities, unlike many other highly publicized industries that have profitably exploited their supply chains. It is, thus, an interesting topic for research. A closer look, however, reveals that our initial assessment of the industry is colored by the popular financial criteria prevalent among analysts and the investing public. This research will suggest that the pharmaceutical industry does care about its supply chain, although, a reevaluation of the supply chain strategy is necessary for addressing problems effectively. In fact, we will argue that an excellent supply chain is paramount to the pharmaceutical industry's success. We subscribe to the view that a supply chain should be considered excellent if it is able to effectively support a business strategy. The business objectives of the pharmaceutical industry include the need to ensure that the drugs are protected from adulteration and counterfeiting, removed and destroyed in a safe and environmentally friendly manner, and made available to patients at all time. Clearly, these are not commonly used metrics to assess the performance of a company or a supply chain.en_US
dc.description.abstract(cont.) Instead, characteristics that have direct impact on the short term financial well being of the company, such as reduced lead times, increased flexibility, and lower cost are the ones that take precedence. As a result, there is a huge gap between the actual and perceived capabilities of the pharmaceutical supply chains. Furthermore, there are clear indications that a radical transformation of the pharmaceutical industry is on the horizon which will require further strengthening of its supply chains, rendering it even more critical to success.en_US
dc.description.statementofresponsibilityby Mahender Singh.en_US
dc.format.extent158 leavesen_US
dc.format.extent8143352 bytes
dc.format.extent8149986 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582
dc.subjectEngineering Systems Division.en_US
dc.titleThe pharmaceutical supply chain : a diagnosis of the state-of-the-arten_US
dc.typeThesisen_US
dc.description.degreeM.Eng.in Logisticsen_US
dc.contributor.departmentMassachusetts Institute of Technology. Engineering Systems Division
dc.identifier.oclc62413418en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record